The Inland Northwest’s
Premier Urologic Practice
Southside Office: (509) 747-3147
Northside Office: (509) 483-6449

Publications

Raymond S. Lance, M.D.

Journal Publications

  1. Moul JW, Lance RS, Theune S, and Bishoff JT:  From Genes That Control Cancer, A New Medicine Rising.  Contemporary Urology, 4:74-87, April 1992.
  2. Moul JW, Lance RS, Theune S, and Bishoff JT:  Probing the Molecular Machine that Drives Prostate Cancer.  Contemporary Urology, 5:62-67, May 1992.
  3. Moul JW, Lance RS, Theune S, and Bishoff JT: Close on the Trail of Genetic Disruptions in Bladder Cancer.  Contemporary Urology, 6:32-39, June 1992.
  4. Moul JW, Lance RS, Theune S, and Bishoff JT: A Range of Genetic Upsets may Contribute to RCC:  Contemporary Urology, 7:28-40, July 1992.
  5. Moul JW, Friedrichs PA, Lance RS, Theune S, and Chang EH: Infrequent RAS Oncogene Mutations in Human Prostate Cancer.  The Prostate, 20:327-338, 1992.
  6. Lance RS, Albo MA, Costabile RA, and Steers WD:  Oral Trazodone as Empirical Therapy for Erectile Dysfunction:  A Retrospective Review.  Urology, 46(1):117-120, 1995.
  7. Peterson AC, Lance RS, and Ruiz HE: Outcomes Analysis of Varicocele Ligation for Pain. Journal of Urology, 159: 1565-1567, 1998.
  8. Lance RS, Aldous, W, Blaser, J, and Thrasher, JB: Telomerase Activity in Solid Transitional Cell Carcinoma, Bladder Washings and Voided Urine. Urologic Oncology, 4: 43-49, 1998.
  9. Brown TA, Aldous W, Lance RS, Blaser J, Baker T, Williard W: The Association Between Telomerase, p53, and Clinical Staging in Colorectal Cancer. Am J Surg, 175(5):364-6, 1998.
  10. Peterson AC, and Lance RS: Malignant lymphoma of the kidney presenting with pain and acute renal failure. Techniques in Urol., 6(3): 218-220, 2000.
  11. Thrasher JB, Robinson JJ, and Lance RS: Comparison of Radical Perineal Prostatectomy to Radical Retropubic Prostatectomy for Localized Prostate Cancer. AUA Update Series, 20: lesson 2, pages 10-15, 2000.
  12. Lance RS, Freidrichs PA, Kane C, Powell CR, Pulos E, Moul JW, McLeod DG, Cornum RL, and Thrasher JB: A Comparison of Radical Retropubic with Perineal Prostatectomy for Localized Prostate Cancer Within the Uniformed Services Urology Research Group. BJU International, 87: 61-65, 2001.
  13. Lance RS, and Grossman HB: Cystectomy in the Elderly. Sem Urologic Onc, 19: 51-55, 2001.
  14. Lance RS, Dinney CPN, Swanson D, Babaian RJ, Pisters LL, Palmer LJ, and Grossman HB: Radical Cystectomy for Invasive Bladder Cancer in the Octogenarian. Oncology Reports, 8: 723-726, 2001.
  15. Sexton WJ, Lance RS, Reyes AO, Pisters PWT, Tu S, and Pisters LL: Adult Prostate Sarcoma:  The M.D. Anderson Cancer Center Experience. J. Urol. 166: 521-525, 2001.
  16. Sun L, Gancarczyk K, Paquette EL, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff J, Soderdahl D, and Moul J:  Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era. Urologic Oncology 6: 203-209, 2001.
  17. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW:  Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58(5): 723-728, 2001.
  18. Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR: Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3.  J Endocrinol. 170(3):609-618, 2001.
  19. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, and Moul JW:  Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy.  Urology 58(5): 723-728, 2001.
  20. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Rich NM: Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 132(2):213-9, 2002.
  21. Peterson AC, Lance RS, and Ahuja SK: Laparoscopic Hand Assisted Radical Cystectomy with Ileal Conduit Urinary Diversion. J. Urol 168: 2103-2105, 2002.
  22. Piper NY, Kusuda L, Lance R, Foley J, Moul J, and Seay T:  Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis. 5(2): 164-166, 2002.
  23. Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff J, Soderdahl D, and Moul J:  Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.  Prostate Cancer Prostatic Dis. 5(3): 212-218, 2002.
  24. Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, and Amling CL: Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology. 225(2): 420-426, 2002.
  25. Johnstone PA, Riffenburgh RH, Moul JW, Sun L, Wu H, McLeod DG, Kane CJ, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Chung A, Soderdahl D, Do J, Amling CL; Department of Defense Center for Prostate Disease Research: Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiation therapy in an equal-access health care system:  a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Biol Phys. 55(4): 964-969, 2003.
  26. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:  Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 61(3): 589-595, 2003.
  27. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 61(3): 607-611, 2003.
  28. Davis R, Peterson AC, Lance R: Clear cell adenocarcinoma in a female urethral diverticulum. Urology. 61(3): 644, 2003.
  29. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T: Pretreatment total testosterone level predicts pathologic stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol.  169(5): 1670-1675, 2003.
  30. Lance RS, and Grossman HB:  Recent developments in the treatment of bladder cancer. Adv. Exp. Med. Biol. 539: 3-14, 2003.
  31. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, and Donahue T: Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol. Oncol. 21(6): 447-455, 2003.
  32. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackman S, and Moul JW: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J. Clin. Oncol. 21(21): 4001-4008, 2003.
  33. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, and McLeod DG: Pathologic Variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.  J. Clin. Oncol. 22(3): 439-445, 2004.
  34. Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, and Soderdahl D: Watchful waiting factors predictive of secondary treatment of localized prostate cancer. J. Urol. 171(3): 1111-1116, 2004.
  35. Langenstroer P, Kramer B, Cutting B, Amling C, Poulton T, Lance R, Thrasher JB:  Parenteral medrosxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J. Urol. 174(2): 642-645, 2005.
  36. Magnuson WJ, Tomera KM, Lance RS: Houndsfield unit density accurately predicts ESWL success. Alaska Medicine 47(2): 6-9, 2005.
  37. Berry T, Tepera C, Staneck D, Barone B, Lance R, Fabrizio M, Given R: Is there correlation of nerve-sparing status and return to baseline urinary function after robotic assisted laparoscopic radical prostatectomy?  J Endourol. 23(3): 489-493, 2009.
  38. White KY, Rodemich L, Nyalwidhe JO, Comunale MA, Clements MA, Lance RS, Schellhammer PF, Mehta AS, Semmes OJ, Drake RR:  Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease in seminal fluids.  J. Proteome Res. 8(2):620-630, 2009.
  39. Cazares LH, Troyer D, Mendrinos S, Lance RS, Beydoun HA, Clements M, Drake RR, Semmes OJ:  Imaging Mass Spectrometry of a specific fragment of MEKK2 discriminates cancer from uninvolved prostate tissue.  Cancer Res. In press, 2009.
  40. Malcolm JB, Berry TT, Williams MB, Logan JE, Given RW, Lance RS, Barone B, Shaves S, Vingan H, Fabrizio MD.  Single center experience with percutaneous and laparoscopic cryoablation of small renal masses.  J Endourol. 23(6):907-11, 2009.
  41. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.  J Proteomics. 72(6):907-17, 2009.[Epub 2009 Jan 20]
  42. Mohan R, Beydoun H, Barnes-Ely ML, Lee L, Davis JW, Lance R, Schellhammer P.  Patients’ survival expectations before localized prostate cancer treatment by treatment status. J Am Board Fam Med. 2009 May-Jun;22(3):247-56.
  43. Karbassi ID, Nyalwidhe JO, Wilkins CE, Cazares LH, Lance RS, Semmes OJ, Drake RR.  Proteomic expression profiling and identification of serum proteins using immobilized trypsin beads with MALDI-TOF/TOF.  J Proteome Res. 8(9):4182-92, 2009.
  44. Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, Lynch DF, Davis JW, Shaves ME, Schellhammer PF.  Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.  J Urol. 183(5):1822-8, 2010. [Epub 2010 Mar 29]
  45. Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T. In-depth proteomic analyses of direct expressed prostatic secretions.  J Proteome Res. 9(5):2109-16, 2010.
  46. Beydoun, H. A., Mohan, R., Beydoun, M. A., Davis, J., Lance, R. and Schellhammer, P. Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer. BJUI, Aug 2010, 106(3): 334–341.
  47. Mohan R, Beydoun HA, Barnes-Eley M, Davis J, Lance R, Schellhammer P. Self-rated health as a tool for estimating health-adjusted life expectancy amoung patients newly diagnosed with localized prostate cancer: a preliminary study. Qual Life Res. 20(5): 713-21, 2011.
  48. Haupt S, Tisdale M, Vincendeau M, Clements MA, Gauthier DT, Lance R, Semmes OJ, Turqueti-Neves A, Noessner E, Lieb-Mosch C, Greenwood AD. Human Endogenous Retrovirus Transcription profiles of the kidney and kidney-derived cell lines. J Gen Virol. 92(10): 2356-2366, 2011.
  49. Lance RS, Drake RR, Troyer DA. Multiple Recognition Assay Reveals Prostasomes as promising plasma biopmarkers for prostate cancer. Expert Rev Anticancer Ther. 11(9): 1341-1343, 2011.
  50. Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA. Molecular Pathology of Prostate Cancer. Cancer Biomark. 9(1-6): 441-459, 2011.
  51. Shuster JR, Lance RS, Troyer DA.  Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol. 2011 Dec 21;11:14.
  52. Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.  J Proteome Res. 11(4):2386-96, 2012.
  53. Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T.  Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 11(12):1870-84, 2012
  54. Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH. NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.  Urology. 80(6):1319-25, 2012.
  55. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 20(1):39-44, 2013
  56. Lambert JW, Ingham M, Gibbs BB, Given RW, Lance RS, Riggs SB. Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer.  Urology. 81(3):587-92, 2013.
  57. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS.  Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 19(9):2442-50, 2013
  58. Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, Semmes OJ, Troyer DA, Lance RS, Kislinger T, Drake RR.  In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics 13(10-11):1667-71, 2013.
  59. Beckham TH, Cheng JC, Lu P, Shao Y, Troyer D, Lance R, Marrison ST, Norris JS, Liu X. Acid ceramidase induces sphingosine kinase 1/S1P receptor 2-mediated activation of oncogenic Akt signaling. Oncogenesis. 3;2:1-11, 2013.
  60. Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, Brooks J, Watson MT, Lance RS, Troyer DA, Semmes OJ, Mehta A, Drake RR.  Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.  Proteomics Clin Appl. Jun 17, 2013.
  61. Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, Esquela-Kerscher A.  miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.  Cell Cycle 13(2): 227-239, 2014.
  62. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Reiger-Christ K, Jones JS, Magi-Galluzi C, Mangold LA, Trock BJ, Lance RS,  Bigley JW, Van Creikinge W: Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 192(4): 1081-1087, 2014.
  63. Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, and Lin D: Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.  Eur Urol. 68(6): 1083-1088, 2015.
  64. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH, Karsh LI, Tscherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, and Figlin RA: Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 21:3-14, 2015.
  65. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, and Shore ND: A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 21(17): 3862-3869, 2015.
  66. Troyer DA, Jamaspishvilli T, Wei W, Feng Z, Good J, Hawley S, Fazil L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD,  and Squire JA: A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.  Prostate 75(11): 1206-1215, 2015.
  67. Wason SE,  Lance RS, Given RW, and Malcom JP: Robotic-Assisted Ureteral Re-implantation: A Case Series. J Laparoendosc Adv Surg Tech A. 25(6): 503-507, 2015.
  68. Fantony JJ, Abern MR, Gopalakrishna A, Owusu R, Jack Tay K, Lance RS, and Inman BA: Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.  Urol Oncol 33(9): 387, 2015.
  69. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, and McKenney JK: Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.  PLoS One 10(7): 1-14, 2015.
  70. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carrol PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Geng Z, Gleave ME, Funju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretia K, Troyer DA, True LD, Vakar-Lopex F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, and Lin DW: Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.    J Urol. 195(2): 313-320, 2016.